Search This Blog

Thursday, September 17, 2026

Xenon pauses new enrollment in Phase 3 after adverse events

 

Xenon Pharmaceuticals pauses new enrollment in Phase 3 psychiatry studies after reviewing neuropsychiatric adverse events

  • Company submits NDA to the FDA for azetukalner as a treatment for focal seizures
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)